Adicet reports fourth quarter and full year 2023 financial results and highlights recent company progress

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended december 31, 2023. “we are excited to explore the potential of our gamma delta t cell platform in autoimmune diseases following the fda's ind clearance of adi-001 in lupus nephri.
ACET Ratings Summary
ACET Quant Ranking